Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1819479 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1819479 (Open-label, Randomised, Two-way Crossover Design)
Latest Information Update: 06 May 2022
At a glance
- Drugs BI 1819479 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 19 Apr 2022 Planned End Date changed from 23 Apr 2022 to 25 Apr 2022.
- 19 Apr 2022 Planned primary completion date changed from 23 Apr 2022 to 25 Apr 2022.